

**CONTACT - Media:**

Amsterdam +31.20.721.4133  
Dublin +353 1 617 4221  
Oslo +47 22 34 17 40

Brussels +32.2.620.15.50  
Lisbon +351.210.600.614  
Paris +33.1.70.48.24.45

**CONTACT - Investor Relations:**

+33.1.70.48.24.17

**IMMUPHARMA LISTS ON EURONEXT GROWTH BRUSSELS**

**Through this dual listing, ImmuPharma, which is already listed on AIM, aims to diversify and enlarge its shareholder base in Continental Europe**

**Brussels, 19 December 2019** – ImmuPharma PLC, (LSE AIM: IMM – Euronext Growth: ALIMM) a specialist drug discovery and development company, today began trading on Euronext Growth Brussels. On the day of listing in Brussels, ImmuPharma’s market capitalisation stood at approx. €33.37 million. The Company did not issue any new shares.

ImmuPharma is headquartered in London and has its research operations in France and Switzerland. The Company is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by high unmet medical need, low marketing costs and relatively low development costs.

The dual listing on Euronext aims to further increase the visibility of ImmuPharma’s shares in Continental Europe and with European investors. This follows the Company’s recent deal with US Avion Pharmaceuticals, who are now funding an international Phase III trial for its lead programme, Lupuzor™.

Euronext Growth, Euronext’s pan-European MTF dedicated to small & mid-caps, recently obtained the EU SME Growth Market status, which facilitates access to capital markets for European SMEs. The companies listed on Euronext Growth now benefit from simplified market processes in two key legislations: the Prospectus Regulation and the Market Abuse Regulation (MAR). Those evolutions are first steps to additional alleviations and benefits expected to be implemented in the years to come for SME Growth Markets.

**Dimitri Dimitriou, ImmuPharma’s CEO, commented:** *“We are delighted to today’s commencement of ImmuPharma’s shares being traded on Euronext Growth Brussels. We have been planning this dual listing for a while. With us recently successfully completing a significant corporate deal on our most advanced drug in development, Lupuzor™, with our US partner, Avion Pharmaceuticals, the timing is appropriate. Euronext is positioned as the number 1 European Stock Exchange for Life Sciences and Brussels is the hub of an ecosystem in the Life Science sector which is knowledgeable, supportive and attractive to a company like ImmuPharma. We would like to specifically thank the Euronext team and our advisors for their invaluable support through this process.”*

To celebrate ImmuPharma's first trading day on Euronext, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, rang the opening bell in Brussels.



#### CONTACTS –

Pascal Brabant (Euronext): +32 2 620 15 50  
[pbrabant@euronext.com](mailto:pbrabant@euronext.com)

For further information about ImmuPharma please contact:

**ImmuPharma PLC ([www.immupharma.com](http://www.immupharma.com))** + 44 (0) 207 152 4080  
 Tim McCarthy, Chairman  
 Dimitri Dimitriou, Chief Executive Officer  
 Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496

**4Reliance (Euronext Growth Listing Sponsor)**  
 Jean-Charles Snoy +32 (0) 2 747 02 60

**Degroof Petercam (Liquidity Provider)**  
 Erik De Clippel +32 (0) 2 287 95 34

**Backstage Communication**  
 Olivier Duquaine +32 (0) 477 504 784  
 Jean-Louis Dubrule +32 (0) 497 50 84 03

#### About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and

development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit [www.immupharma.com](http://www.immupharma.com).

#### **About Euronext**

Euronext is the leading pan-European exchange, covering Belgium, France, Ireland, The Netherlands, Norway, Portugal and the UK. With close to 1,500 listed issuers worth €4.3 trillion in market capitalisation as of end September 2019, Euronext has an unmatched blue chip franchise that includes 26 issuers in the Morningstar® Eurozone 50 Index<sup>SM</sup> and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext Growth<sup>TM</sup> and Euronext Acces<sup>TM</sup>, simplifying access to listing for SMEs. The Norwegian stock exchange and its clearing & settlement subsidiary, together operating as Oslo Børs VPS, joined Euronext on 17 June 2019.

For the latest news, find us on Twitter ([twitter.com/euronext](https://twitter.com/euronext)) and LinkedIn ([linkedin.com/euronext](https://linkedin.com/euronext)).

#### **Disclaimer**

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided “as is”, without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2019, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, “GDPR”), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: <https://www.euronext.com/en/privacy-policy>.

In accordance with the applicable legislation you have rights with regard to the processing of your personal data:

- for more information on your rights, please refer to: [https://www.euronext.com/data\\_subjects\\_rights\\_request\\_information](https://www.euronext.com/data_subjects_rights_request_information),
- to make a request regarding processing of your data or to unsubscribe to this press release service, please use our data subject request form at <https://connect2.euronext.com/form/data-subjects-rights-request> or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).